Ocumension Therapeutics (HKG:1477) received approval from China's National Medical Products Administration for the new drug application of OT-502, according to a Thursday Hong Kong bourse filing.
OT-502, marketed as DEXYCU and Shishu, is a single-dose, sustained-release dexamethasone intraocular suspension indicated for the treatment of postoperative ocular inflammation.
Celltrion (KRX:068270) posted second-quarter sales of 1.3 trillion won, up 35% from 961.5 billion won a year earlier, according to a Friday filing with the Korea Exchange.The South Korean biopharmaceutical company's operating income jumped 77% year over year to 430 billion won from 242.5 billion won, the filing said.Shares of Celltrion rose nearly 4% in recent trade.
Elite UK REIT (SGX:MXNU) disposed of four properties in Wales, UK, for 6 million pounds sterling, according to a Thursday filing with the Singapore Exchange.Shares of the REIT were up nearly 2% in Friday trading.Proceeds from the divestments will be used for high-quality or high-growth opportunities, the REIT said.
XMH's (SGX:BQF) attributable profit to owners jumped 25% during the fiscal second half ended April 30 to SG$16.1 million from SG$12.9 million a year earlier, according to a Thursday filing with the Singapore Exchange.Earnings per share came in at SG$0.1470 compared with SG$0.1180 in the year-ago period.Revenue declined 8.8% year over year to SG$91.4 million from SG$100.2 million.The marine industry power generation company declared a special interim dividend of SG$0.03 per share, a final dividend of SG$0.0025 per share and a special dividend of SG$0.0775 per share for the period.